1. Scrip
  2. >>R&D

Wave’s Huntington Drugs Wipe Out As Trials Run Aground

WVE-120102 And WVE-120101 Fail To Show Benefit

 
• By Alaric DeArment

The company now turns to its next-generation Huntington drug, WVE-003.

Amazing, perfect wave - Image
Wave is moving on to next-generation drug WVE-003 after its first-generation Huntington drugs failed. • Source: Shutterstock

WAVE Life Sciences Ltd. is banking on its next-generation asset for Huntington disease (HD) after the failure of a clinical trial program of two earlier-generation drugs, which itself closely follows Roche Holding AG’s discontinuation of its own HD trial. Wave is hoping that the new drug’s improved preclinical pharmacology will raise the odds of success.

The Cambridge, MA-based company announced 29 March that data from the Phase Ib/IIa PRECISION-HD2 study of WVE-120102 and the PRECISION-HD1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

More from Scrip

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By Mandy Jackson

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.